[Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]
- PMID: 19809923
- DOI: 10.4321/s0365-66912009000900003
[Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]
Abstract
Objective: Diabetes mellitus is considered the most common cause of blindness in the working population of industrialized countries, with diabetic macular edema being the most common cause of decreased visual acuity and proliferative diabetic retinopathy (PDR) being responsible for the most severe visual deficits. We have therefore tried to establish a guide for clinical intervention whose purpose is to provide orientation on the treatment of diabetic retinopathy and its complications. This is necessary at a time when many treatment options have emerged whose role is not yet fully defined.
Method: A group of expert retina specialists selected by the SERV (Vitreous-Retina Spanish Society) assessed the published results of different treatment options currently available, suggesting lines of action according to the degree of diabetic retinopathy present and the presence or absence of macular edema.
Results: PDR is primarily treated with pan-retinal photocoagulation. For clinically significant diabetic macular edema without signs of vitreomacular traction, the treatment of choice continues to be focal/grid photocoagulation. Similarly, retinovitreal surgery is indicated for both conditions. The use of antiangiogenic drugs was also analyzed but remains inconclusive.
Conclusion: Laser therapy is effective in the management of diabetic retinopathy and diabetic macular edema. The role of antiangiogenics is not yet sufficiently defined.
Similar articles
-
Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.Retina. 2006 Nov-Dec;26(9):999-1005. doi: 10.1097/01.iae.0000247165.38655.bf. Retina. 2006. PMID: 17151486 Clinical Trial.
-
Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48. Retina. 2008. PMID: 18779710
-
Management of cataract with macular oedema due to diabetes mellitus type-II and hypertension with grid laser prior to surgery and intra-vitreal bevacizumab (Avastin) peroperatively.J Pak Med Assoc. 2010 Oct;60(10):836-9. J Pak Med Assoc. 2010. PMID: 21381615
-
[Angiopathy and the eye].Vnitr Lek. 2010 Apr;56(4):333-9. Vnitr Lek. 2010. PMID: 20465107 Review. Czech.
-
Intravitreal bevacizumab for diabetic retinopathy.Curr Diabetes Rev. 2009 Feb;5(1):39-46. doi: 10.2174/157339909787314121. Curr Diabetes Rev. 2009. PMID: 19199897 Review.
Cited by
-
Searching for the Antioxidant, Anti-Inflammatory, and Neuroprotective Potential of Natural Food and Nutritional Supplements for Ocular Health in the Mediterranean Population.Foods. 2021 May 28;10(6):1231. doi: 10.3390/foods10061231. Foods. 2021. PMID: 34071459 Free PMC article. Review.
-
Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain.Clin Ophthalmol. 2022 Sep 19;16:3097-3106. doi: 10.2147/OPTH.S374763. eCollection 2022. Clin Ophthalmol. 2022. PMID: 36164581 Free PMC article.
-
Current trends in the monitoring and treatment of diabetic retinopathy in young adults.Mediators Inflamm. 2014;2014:492926. doi: 10.1155/2014/492926. Epub 2014 Feb 13. Mediators Inflamm. 2014. PMID: 24688225 Free PMC article. Review.
-
[Evaluation of the management and follow-up of diabetic patients in the prevention of diabetic retinopathy].Rev Esp Salud Publica. 2024 Apr 10;98:e202404030. Rev Esp Salud Publica. 2024. PMID: 38597266 Free PMC article. Spanish.
-
Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.BMC Ophthalmol. 2020 Sep 17;20(1):371. doi: 10.1186/s12886-020-01637-0. BMC Ophthalmol. 2020. PMID: 32943041 Free PMC article.